| Adam M Franks, MD | |
|
1600 Medical Center Dr, Suite 1500, Huntington, WV 25701-3656 | |
| (304) 691-1100 | |
| (304) 691-1183 |
| Full Name | Adam M Franks |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 1600 Medical Center Dr, Huntington, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063473072 | NPI | - | NPPES |
| 2334969 | Medicaid | OH | |
| 1812317000 | Medicaid | WV | |
| 64053291 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 20377 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cabell Huntington Hospital Inc | Huntington, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physicians And Surgeons, Inc | 2961315734 | 324 |
News Archive
The Senate overwhelmingly passed significant prescription drug safety reforms to give the Food and Drug Administration more power to deal with unsafe medicines on the market, moving the issue of drug safety to the House, where a strong bill has been introduced but has yet to be considered.
Pain distribution as reported on a body map, on its own, can be used to assign patients to distinct subgroups that are associated with differences in pain intensity, pain quality, pain impact and clinically-relevant three-month outcomes, according to a new study published this week in the open-access journal PLOS ONE by Benedict Alter of University of Pittsburgh, US, and colleagues.
A multi-center clinical trial led by a Riley Hospital for Children endocrinologist has found that inhaled growth hormone (GH) is well tolerated by children with GH deficiency and that this easy-to-use method can, over a one-week period, safely deliver GH to the blood stream. In addition to having implications for those who need GH, this first pediatric study of administering it through the lungs may also help researchers interested in using this convenient method for effectively delivering other types of medications to children.
Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.
› Verified 3 days ago
| Entity Name | University Physicians & Surgeons, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730183286 PECOS PAC ID: 2961315734 Enrollment ID: O20031107000331 |
News Archive
The Senate overwhelmingly passed significant prescription drug safety reforms to give the Food and Drug Administration more power to deal with unsafe medicines on the market, moving the issue of drug safety to the House, where a strong bill has been introduced but has yet to be considered.
Pain distribution as reported on a body map, on its own, can be used to assign patients to distinct subgroups that are associated with differences in pain intensity, pain quality, pain impact and clinically-relevant three-month outcomes, according to a new study published this week in the open-access journal PLOS ONE by Benedict Alter of University of Pittsburgh, US, and colleagues.
A multi-center clinical trial led by a Riley Hospital for Children endocrinologist has found that inhaled growth hormone (GH) is well tolerated by children with GH deficiency and that this easy-to-use method can, over a one-week period, safely deliver GH to the blood stream. In addition to having implications for those who need GH, this first pediatric study of administering it through the lungs may also help researchers interested in using this convenient method for effectively delivering other types of medications to children.
Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adam M Franks, MD 1600 Medical Center Dr, Suite 1500, Huntington, WV 25701-3656 Ph: (304) 691-1100 | Adam M Franks, MD 1600 Medical Center Dr, Suite 1500, Huntington, WV 25701-3656 Ph: (304) 691-1100 |
News Archive
The Senate overwhelmingly passed significant prescription drug safety reforms to give the Food and Drug Administration more power to deal with unsafe medicines on the market, moving the issue of drug safety to the House, where a strong bill has been introduced but has yet to be considered.
Pain distribution as reported on a body map, on its own, can be used to assign patients to distinct subgroups that are associated with differences in pain intensity, pain quality, pain impact and clinically-relevant three-month outcomes, according to a new study published this week in the open-access journal PLOS ONE by Benedict Alter of University of Pittsburgh, US, and colleagues.
A multi-center clinical trial led by a Riley Hospital for Children endocrinologist has found that inhaled growth hormone (GH) is well tolerated by children with GH deficiency and that this easy-to-use method can, over a one-week period, safely deliver GH to the blood stream. In addition to having implications for those who need GH, this first pediatric study of administering it through the lungs may also help researchers interested in using this convenient method for effectively delivering other types of medications to children.
Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.
› Verified 3 days ago
Jessica D Wilson, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2520 Valley Drive, Huntington, WV 25702 Phone: 304-675-4340 | |
Katherine Steele, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Medical Center Dr, Suite 1500, Huntington, WV 25701 Phone: 304-691-1100 Fax: 304-691-1153 | |
Carrie Marie Dillard, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1340 Hal Greer Blvd, Huntington, WV 25701 Phone: 304-526-2319 Fax: 304-526-2420 | |
Janet Nease Wallace, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 1st Ave, Opc Suite 30, Huntington, WV 25702 Phone: 304-399-7280 Fax: 304-399-7282 | |
Scott W Mitchell, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1400 Hal Greer Blvd, Huntington, WV 25701 Phone: 304-399-6515 Fax: 304-399-6667 | |
Deidre E Parsley, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2900 First Avenue, Huntington, WV 25702 Phone: 304-399-7484 Fax: 304-399-7579 |